|
1
|
Koul H, Huh JS, Rove KO, Crompton L, Koul
S, Meacham RB and Kim FJ: Molecular aspects of renal cell
carcinoma: A review. Am J Cancer Res. 1:240–254. 2011.PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ahrens M, Scheich S, Hartmann A and
Bergmann L; IAG-N Interdisciplinary Working Group Kidney Cancer of
the German Cancer Society, : Non-clear cell renal cell
carcinoma-pathology and treatment options. Oncol Res Treat.
42:128–135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of Renal Cell Carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruchbacher A, Lemberger U, Hassler MR,
Fajkovic H and Schmidinger M: PD1/PD-L1 therapy in metastatic renal
cell carcinoma. Curr Opin Urol. 30:534–541. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bedke J, Albiges L, Capitanio U, Giles RH,
Hora M, Lam TB, Ljungberg B, Marconi L, Klatte T, Volpe A, et al:
Updated European Association of Urology guidelines on renal cell
carcinoma: Nivolumab plus cabozantinib joins immune checkpoint
inhibition combination Therapies for treatment-naive metastatic
clear-cell renal cell carcinoma. Eur Urol. 79:339–342. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang L, Zou X, Zou J and Zhang G: A review
of recent research on the role of MicroRNAs in renal cancer. Med
Sci Monit. 27:e9306392021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maher ER: Hereditary renal cell carcinoma
syndromes: Diagnosis, surveillance and management. World J Urol.
36:1891–1898. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Testa JR, Cheung M, Pei J, Below JE, Tan
Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al: Germline
BAP1 mutations predispose to malignant mesothelioma. Nat Genet.
43:1022–1025. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmidt L, Duh FM, Chen F, Kishida T,
Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al:
Germline and somatic mutations in the tyrosine kinase domain of the
MET proto-oncogene in papillary renal carcinomas. Nat Genet.
16:68–73. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang G, Lai Y, Pan X, Zhou L, Quan J,
Zhao L, Li Z, Lin C, Wang J, Li H, et al: Tumor suppressor
miR-33b-5p regulates cellular function and acts a prognostic
biomarker in RCC. Am J Transl Res. 12:3346–3360. 2020.PubMed/NCBI
|
|
13
|
Chen FY, Zhou ZY, Zhang KJ, Pang J and
Wang SM: Long non-coding RNA MIR100HG promotes the migration,
invasion and proliferation of triple-negative breast cancer cells
by targeting the miR-5590-3p/OTX1 axis. Cancer Cell Int.
20:5082020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo ZF, Peng Y, Liu FH, Ma JS, Hu G, Lai
SL, Lin H, Chen JJ, Zou GM, Yan Q and Sui WG: Long noncoding RNA
SNHG14 promotes malignancy of prostate cancer by regulating with
miR-5590-3p/YY1 axis. Eur Rev Med Pharmacol Sci. 24:4697–4709.
2020.PubMed/NCBI
|
|
15
|
Wu N, Han Y, Liu H, Jiang M, Chu Y, Cao J,
Lin J, Liu Y, Xu B and Xie X: MiR-5590-3p inhibited tumor growth in
gastric cancer by targeting DDX5/AKT/m-TOR pathway. Biochem Biophys
Res Commun. 503:1491–1497. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Y, Dong MH, Hu HM, Min QH and Xiao L:
LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and
metastasis of renal cell carcinoma through ERK/AKT signalling. Eur
Rev Med Pharmacol Sci. 24:8756–8766. 2020.PubMed/NCBI
|
|
17
|
Sharma P and Roy K: ROCK-2-selective
targeting and its therapeutic outcomes. Drug Discov Today.
25:446–455. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei L, Surma M, Shi S, Lambert-Cheatham N
and Shi J: Novel insights into the roles of rho kinase in cancer.
Arch Immunol Ther Exp (Warsz). 64:259–278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Sousa GR, Vieira GM, das Chagas PF,
Pezuk JA and Brassesco MS: Should we keep rocking? Portraits from
targeting Rho kinases in cancer. Pharmacol Res. 160:1050932020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Z, Hong Z, Ma M, Liu X, Chen L, Zheng
C, Xi X and Shao J: Rock2 promotes RCC proliferation by decreasing
SCARA5 expression through β-catenin/TCF4 signaling. Biochem Biophys
Res Commun. 480:586–593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marchetti A, Rosellini M, Mollica V, Rizzo
A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M,
Montironi R and Massari F: The molecular characteristics of
non-clear cell renal cell carcinoma: What's the story morning
glory? Int J Mol Sci. 22:62372021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma R, Kadife E, Myers M, Kannourakis
G, Prithviraj P and Ahmed N: Determinants of resistance to VEGF-TKI
and immune checkpoint inhibitors in metastatic renal cell
carcinoma. J Exp Clin Cancer Res. 40:1862021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mlcochova H, Machackova T, Rabien A,
Radova L, Fabian P, Iliev R, Slaba K, Poprach A, Kilic E, Stanik M,
et al: Epithelial-mesenchymal transition-associated microRNA/mRNA
signature is linked to metastasis and prognosis in clear-cell renal
cell carcinoma. Sci Rep. 6:318522016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhat S: Role of surgery in
advanced/metastatic renal cell carcinoma. Indian J Urol.
26:167–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: MicroRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Çaykara B, Ozturk G, Alsaadoni H,
Otunctemur A and Pence S: Evaluation of MicroRNA-124 expression in
renal cell carcinoma. Balkan J Med Genet. 23:73–78. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He X, Liao S, Lu D, Zhang F, Sun Y and Wu
Y: MiR-125b promotes migration and invasion by targeting the
vitamin D receptor in renal cell carcinoma. Int J Med Sci.
18:150–156. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng C, Guo L, Ma Y, Wang Z, Fan X and
Shan Z: Up-Regulation of miR-26a-5p Inhibits E2F7 to regulate the
progression of renal carcinoma cells. Cancer Manag Res.
12:11723–11733. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang W, Wu Y, Hou B, Wang Y, Deng D, Fu Z
and Xu Z: A SOX9-AS1/miR-5590-3p/SOX9 positive feedback loop drives
tumor growth and metastasis in hepatocellular carcinoma through the
Wnt/β-catenin pathway. Mol Oncol. 13:2194–2210. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang Y, Dong MH, Hu HM, Min QH and Xiao L:
LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and
metastasis of renal cell carcinoma through ERK/AKT signalling. Eur
Rev Med Pharmacol Sci. 24:8756–8766. 2020.PubMed/NCBI
|
|
32
|
Du Y, Lu S, Ge J, Long D, Wen C, Tan S,
Chen L and Zhou W: ROCK2 disturbs MKP1 expression to promote
invasion and metastasis in hepatocellular carcinoma. Am J Cancer
Res. 10:884–896. 2020.PubMed/NCBI
|
|
33
|
Deng X, Yi X, Huang D, Liu P, Chen L, Du Y
and Hao L: ROCK2 mediates osteosarcoma progression and TRAIL
resistance by modulating O-GlcNAc transferase degradation. Am J
Cancer Res. 10:781–798. 2020.PubMed/NCBI
|
|
34
|
Deng B, Deng J, Yi X, Zou Y and Li C:
ROCK2 promotes osteosarcoma growth and glycolysis by up-regulating
HKII via Phospho-PI3K/AKT signalling. Cancer Manag Res. 13:449–462.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo J, Lou Z and Zheng J: Targeted
regulation by ROCK2 on bladder carcinoma via Wnt signaling under
hypoxia. Cancer Biomark. 24:109–116. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qiu Y, Yuan R, Zhang S, Chen L, Huang D,
Hao H and Shao J: Rock2 stabilizes β-catenin to promote tumor
invasion and metastasis in colorectal cancer. Biochem Biophys Res
Commun. 467:629–637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer; Berlin, Germany: pp. 79–81. 2017, PubMed/NCBI
|
